Venus Remedies x Infex to Combat Antimicrobial Resistance in India

Congratulations, Venusians. We have yet again marked another day on the calendar with gold!

Venus Remedies Ltd. is delighted to announce a significant partnership with UK-based anti-infective drug development company, Infex Therapeutics. The alliance aims to tackle drug-resistant Gram-negative bacterial infections via MET-X, an innovative metallo-beta-lactamase (MBL) inhibitor.  

Under this exclusive license agreement, we are looking to integrate MET-X with meropenem to tackle Antimicrobial resistance (AMR). Also, Venus Remedies will lead the clinical development, regulatory registration, and commercialisation of MET-X in India. 

While no approved MBL inhibitors currently exist in the country, we are certain to mark a strategic step against the rising threat of AMR. 

The phase I trials of the examination will evaluate the effect of MET-X-infused meropenem on healthy volunteers. Following the positive outcome, phase II will target drug-resistant Complicated Urinary Tract Infections (cUTIs), prevalent in hospital settings.

Mr. Saransh Choudhary, President Global Critical Care, Venus Remedies, said that the product is expected to hit the market around 2031, subject to regulatory approvals. Alongside, our shares were trading 2.96 per cent up at Rs 316.15 apiece on the BSE.

Driven by the Venusians' unwavering dedication, we are moving forward—stronger, bolder, and determined.